Benjamin Toogood

Benjamin Toogood currently works at invoX Pharma Ltd., as Chief Executive Officer & Director from 2023, Karolinska Development AB, as Chairman from 2024, Pharmathen International SA, as Director & Vice President-Business Development from 2006, Softhale NV, as Director, PHion Therapeutics Ltd., as Director, and Sino Biopharmaceutical Ltd., as Head-Globalization from 2021.
Mr. Toogood also formerly worked at Sandoz AG, as Global Head-Business Development and Pharmathen SA, as Vice President-Business Development.
Mr. Toogood received his graduate degree from the University of the Witwatersrand, undergraduate degree from Rhodes University, and Masters Business Admin degree from the University of Cambridge.